6.43
+1.10%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Immatics
Its shares trade under the ticker IMTX. It has been listed since 2 July 2020. In the fiscal year to 31 December 2025, it reported revenue of €56.4m and a net loss of €229.4m. At that date it held total assets of €656.5m and shareholders' equity of €565.2m.
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg. The company went IPO on 2020-07-02. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Jul 2020
- Employees
- 304
- Website
- immatics.com ↗
- Head office
- PAUL EHRLICH-STRASSE 15, TUBINGEN, 2M, 72076
- Incorporated in
- P7
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Mr. Peter ChambreNon-Executive Chairman of the Board, since 2020€370,000
- Dr. Harpreet SinghChief Executive Officer, Executive Director, since 2020€3.5m
- Mr. Arnd ChristChief Financial Officer
- Dr. Steffen WalterChief Operating Officer, since 2023
- Mr. Edward SturchioGeneral Counsel
- Dr. Cedrik BrittenChief Medical Officer
- Dr. Rainer KramerChief Business Officer
- Dr. Carsten ReinhardtChief Development Officer
- Dr. Toni WeinschenkChief Innovation Officer
- Dr. Mathias HothumNon-Executive Director€317,000
- Dr. Alise ReicinTemporary Non-Executive Director€232,000
- Mr. Michael AtiehNon-Executive Independent Director€353,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Immatics NV employs 304 employees in Tuebingen, Germany, focusing on biotechnology research.
- The company has eight therapeutic programs, four in clinical trials for solid tumors and hematological cancers.
- Immatics NV's pipeline includes IMA201, IMA202, and IMA203 targeting MAGEA4/8, MAGEA1, and PRAME antigens.
Weaknesses
- Immatics NV has 210 full-time employees, which is lower than industry averages for clinical stage biopharmaceuticals.
- The company's IPO on 2 July 2020 marks a relatively recent market entry for a clinical stage firm.
- Immatics NV's focus on T cell receptor-based therapies limits its therapeutic scope compared to broader biotech competitors.
Opportunities
- Immatics NV's ACTolog IMA 101 program targets solid cancers in a multi-target pilot trial.
- The company's TCER modality offers potential for treating solid tumors with antibody-like TCR bispecifics.
- Immatics NV's preclinical programs like IMA204 and IMA401 could expand its solid cancer treatment portfolio.
Threats
- Immatics NV faces competition from established biotech firms in the Health Care sector.
- The clinical trial status of IMA201, IMA202, and IMA203 may delay market entry for these therapies.
- Regulatory hurdles in the European Union could impact Immatics NV's development timelines.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.